Theratechnologies Resumes Distribution of EGRIFTA SV
Theratechnologies Inc. announced a significant step forward in its operations, resuming the distribution of EGRIFTA SV (tesamorelin for injection). This announcement comes after essential communication from the U.S. Food and Drug Administration (FDA), allowing the release of two newly manufactured batches of the medication. The product is now ready for immediate shipment to network pharmacies.
Commitment to HIV Treatment
Christian Marsolais, PhD, Senior Vice President and Chief Medical Officer at Theratechnologies, emphasized the company's dedication to providing EGRIFTA SV to individuals living with HIV. He expressed gratitude towards the FDA for their assistance in returning this much-needed treatment to patients who depend on it.
Ongoing FDA Review
The company is in the process of an ongoing review of its Prior Approval Supplement (PAS) with the FDA. The action goal date for this review is set for a future date. This review is crucial for ensuring that EGRIFTA SV remains available for those who need it most.
About Theratechnologies
Theratechnologies is a biopharmaceutical company with a strong focus on innovative therapies designed to improve healthcare standards. Their commitment to redefining care standards is crucial in a market that strives for better treatment options for various diseases.
Product Availability
EGRIFTA SV is exclusively distributed in the United States, a critical factor in ensuring that patients in need can access this medication quickly and efficiently. Theratechnologies aims to meet the pharmaceutical needs of these patients without delay.
Looking Towards the Future
While the resumption of distribution marks a positive development, the company remains aware of the potential challenges that lie ahead. The busyness of the pharmaceutical landscape presents numerous obstacles, but Theratechnologies is prepared to navigate these challenges to continue supporting HIV patients and their families.
Monitoring Market Demand
As the company moves forward, it continues to assess market demand for EGRIFTA SV amidst previous drug shortages. The management believes in the critical nature of understanding patient needs and remaining responsive to any changes in the market.
Frequently Asked Questions
What does the resumption of EGRIFTA SV distribution mean for patients?
This resumption signifies that patients can once again access this important HIV treatment through network pharmacies, ensuring continuity of care.
What steps are being taken by Theratechnologies for the FDA review?
Theratechnologies is closely monitoring the ongoing FDA review of its Prior Approval Supplement, anticipating a decision within the designated timeline.
How does EGRIFTA SV benefit HIV patients?
EGRIFTA SV is designed to help reduce visceral fat in people living with HIV, a significant health concern associated with the disease.
Is EGRIFTA SV available outside the United States?
Currently, EGRIFTA SV is distributed exclusively in the United States, focusing on providing comprehensive care to domestic patients.
What is Theratechnologies' mission?
Theratechnologies aims to revolutionize treatment standards in biopharmaceutical care, prioritizing innovative therapies that enhance the quality of life for patients.
